This webinar explores prostate-specific membrane antigen (PSMA) positron emission tomography/CT. This technique is becoming increasingly popular for the primary staging of prostate cancer, due to the simultaneous assessment of whole-body disease burden with superior sensitivity and specificity for detecting metastases, compared to conventional imaging. Expert Juan Gómez Rivas, Hospital Clínico San Carlos in Madrid, Spain, dives into the potential benefits and drawbacks of this technique on staging, and addresses the question of whether it should drive our decision-making in prostate cancer.
Themes covered include:
- current treatment options for metastatic hormone sensitive prostate cancer;
- guidelines on prostate cancer;
- the impact of PSMA on management and prognosis; and
- why the use of PSMA should be limited in primary staging.
Juan Gómez Rivas is a urologist at the Hospital Clínico San Carlos in Madrid, Spain, and Associate Professor at the Complutense University of Madrid. He received his medical degree in 2007, and his PhD in 2017. He also obtained a Master’s degree in Management and Administration of Medical Centres and Hospitals, and a Master’s degree in Kidney Cancer and Prostate Cancer.
His healthcare activity is focused on the field of genitourinary tumours, from localised disease to advanced stages, covering both medical and surgical management in different approaches of prostate and bladder cancer, among others. Rivas is active in several scientific societies, and participates in research as a member of the Health Research Institute of the Hospital Clínico San Carlos (IdISSC). His extensive curriculum is completed with the authorship and collaboration of more than 250 scientific publications, special issues, book chapters, and participation in national and international meetings and congresses.